Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · §5

Discontinued development programmes as evidence — amendment log

Every change made since protocol registration, with its date and reason.

Document identifier
CEI-ES-023/5
Series
Evidence synthesis
Version
1.1
Published
09 Apr 2024
Last reviewed
09 Sep 2024
Next review
09 Mar 2026
Identifier
10.71829/cei.syn.23
Certainty
Moderate
Cycle
2024 Q2
Review type
Methodological review
Search executed
13 Jan 2024

§5Amendment log

Every change made to this review after protocol registration is recorded below with its date and its reason. A change that is not in this log did not happen. The Institute publishes the log in full, including changes that did not alter a conclusion, because a reader cannot judge which changes matter unless all of them are visible.

§5.1Amendment log

Table 9. Amendments to this review since protocol registration.

DateVersionAmendmentRecord
24 Dec 20230.1Protocol registeredThe review protocol was registered with the Institute’s secretariat before the search was executed. No change to the review question was made after registration.
17 May 20241.1Analysis method changedThe pooling method was changed from a fixed-effect to a random-effects model following observation of between-study heterogeneity exceeding the pre-specified threshold.
20 Jan 20251.2Comment-period disposition appliedAmendments arising from the disposition of a public comment period were applied. Each amendment is traceable to a numbered submission.
23 Aug 20251.3Outcome addedAn additional outcome was added at the request of a public comment-period respondent. The addition is recorded here because it was made after protocol registration and is therefore post hoc.
18 Mar 20261.0Study reclassifiedA study previously included was reclassified as ineligible following retrieval of the full report. The quantitative synthesis was re-run without it.
Current version 1.1, ratified in the 2024 Q2 assessment cycle.

§5.2Clinical study report requests

Table 10. Clinical study reports requested for the contributing trials, and the outcome of each request. Refusals are recorded because a review that does not record them presents the sponsor's disclosure decision as the Institute's own.

TrialRequestedOutcome
DANU-PH2B-OBESITY06 Nov 2023Refused
DANU-PH2B-T2D06 Dec 2023Redirected to a data-access portal
CELIAC-PH3-CEDLARA27 Dec 2023Partially supplied
MMPOWER-303 Jan 2024Supplied on request
ELAM-PH2-HFPEF03 Nov 2023No response
MMPOWER-229 Dec 2023Partially supplied
AOD-OA-PH219 Dec 2023Refused
CELIAC-PH2B26 Nov 2023Redirected to a data-access portal

§5.3Superseded versions

Superseded versions of this review remain published at a stable address, are marked as superseded, and link forward to the current version. The current version links back to each of them. That practice was adopted following a submission that a document cited in the literature must remain retrievable in the form in which it was cited; the reasoning is published on the corrections policy disposition page.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.